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Relationship between Device Size and Body Weight in Dogs with
Patent Ductus Arteriosus Undergoing Amplatz Canine Duct Occluder
Deployment
S. Wesselowski , A.B. Saunders, and S.G. Gordon
Background: Deployment of the Amplatz Canine Duct Occluder (ACDO) is the preferred method for minimally invasive
occlusion of patent ductus arteriosus (PDA) in dogs, with appropriate device sizing crucial to successful closure. Dogs of any
body weight can be aﬀected by PDA.
Objectives: To describe the range of ACDO sizes deployed in dogs of various body weights for improved procedural plan-
ning and inventory selection and to investigate for correlation between minimal ductal diameter (MDD) and body weight.
Animals: A total of 152 dogs undergoing ACDO deployment between 2008 and 2016.
Methods: Body weight, age, breed, sex, and MDD obtained by angiography (MDD-A), MDD obtained by trans-
esophageal echocardiography (MDD-TEE), and ACDO size deployed were retrospectively evaluated.
Results: Correlation between body weight and ACDO size, MDD-A and MDD-TEE was poor, with R-squared values of
0.4, 0.36, and 0.3, respectively. Femoral artery diameter in the smallest population of dogs placed inherent limitations on the
use of larger device sizes, with no limitations on the wide range of device sizes required as patient size increased. The most
commonly used ACDO devices were size 3 through 6, representing 57% of the devices deployed within the entire study popu-
lation.
Conclusions and Clinical Importance: Patent ductus arteriosus anatomy varies on an individual basis, with poor correla-
tion between MDD and body weight. Weight-based assumptions about expected ACDO device size for a given patient are
not recommended.
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Patent ductus arteriosus (PDA) is 1 of the most com-mon congenital heart defects in dogs.1,2 It aﬀects a
variety of diﬀerent breeds over a large range of body
sizes. Minimally invasive transvascular occlusion with
the Amplatz canine duct occluder (ACDO)a has become
the preferred treatment method for most veterinary car-
diologists, with lower complication rates, more complete
occlusion, and superior ease of use reported in compar-
ison with other devices.3–6 When using the ACDO,
careful assessment of ductal anatomy, in particular the
minimal ductal diameter (MDD), is critical for appro-
priate device selection and successful PDA occlusion.4,5
Although rare or uncommonly reported, embolization
of the device can occur and may be related to inappro-
priate device sizing.5
Anatomy of the PDA can vary substantially from
dog to dog. Previous work presenting an angiographic
classiﬁcation scheme of PDA morphology in the dog
described 4 anatomic variations, with a signiﬁcantly
larger MDD associated with type III morphology com-
pared to types I, IIA, and IIB.7 Type III morphology
is overrepresented in the German Shepherd breed, and,
in many instances, precludes successful use of an
ACDO.7–9 Speciﬁc breed predilections for the other
PDA morphologies have not been reported. Addition-
ally, correlation between body weight and MDD mea-
sured angiographically was not previously appreciated.7
Given the importance of appropriate device sizing,
awareness of the range of potential device sizes needed
for dogs of various body weights could prove clinically
useful for procedural planning and inventory selection.
This is particularly true in settings in which transtho-
racic echocardiography (TTE) is relied upon to assess
MDD for preprocedural inventory ordering, because
MDD as measured by TTE diﬀers signiﬁcantly from
MDD measured by angiography.10
The objective of our study was to describe the range
of ACDO sizes used for PDA occlusion in dogs of vari-
ous body weight ranges presented over an 8-year period
since the device became available for use. In addition,
the relationship between MDD measured both
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angiographically and by transesophageal echocardiogra-
phy (TEE) and body weight was further investigated for
evidence of correlation.
Materials & Methods
A search of the Texas A&M University Veterinary Medical
Teaching Hospital’s veterinary medical information system and
catheterization procedures log identiﬁed 152 dogs diagnosed with
PDA that underwent placement of an ACDO between January
2008 and December 2016. The body weight, age, breed, sex,
and MDD obtained from angiography (MDD-A), MDD
obtained from transesophageal echocardiography (MDD-TEE),
and ACDO size deployed were recorded for each dog when
available. Any dogs with device embolization or with placement
that varied from the original description4,5 were noted. All
MDD measurements were obtained by a single operator (AS),
either at the time of ACDO placement, or upon subsequent
review. Devices were sized as previously described, with the
waist of the ACDO device being oversized by approximately
200% compared to the MDD and the ratio between the PDA
ampulla diameter and the proximal disk of the ACDO being
oversized by approximately 130%.6
Statistics
Body weight data were plotted against ACDO size, MDD-A,
and MDD-TEE in scatterplot form. Simple linear regression and
calculation of the coeﬃcient of determination or R-squared (R2)
then were determined to assess the percentage of variation in these
variables that was attributable to body weight.
Results
One hundred and ﬁfty-two dogs had ACDO devices
placed during the study period. Forty-four breeds were
represented in addition to dogs of mixed breed origin.
Mixed breed dogs were most common (n = 23), fol-
lowed by German Shepherds (n = 19), Bichon Frise
(n = 10), Poodles (n = 7), and Labrador Retrievers
(n = 7). There were 104 females (44 neutered) and 48
males (18 neutered). The average age was 21.5 months
(median, 9.2 months; range, 2–193 months), and the
average body weight was 12.9 kg (median, 9.4 kg;
range, 2.2–37.2 kg). The patient population was
divided into 8 groups based on body weight in incre-
ments of 5 kg. The range of ACDO device sizes
deployed within each weight group and the number of
individual devices of each size utilized are presented in
Table 1. The relationship between body weight and
ACDO size within the entire study population is
depicted in scatterplot form in Figure 1. The R2 for
this relationship was 0.40.
The MDD-A measurement was available in 150 dogs,
whereas the MDD-TEE measurement was available in
122 dogs. The MDD-A ranged from 1 mm to 6.4 mm,
whereas MDD-TEE ranged from 1.2 mm to 8.7 mm.
The relationship between body weight and MDD-A
resulted in an R2 value of 0.36, whereas the relationship
between body weight and MDD-TEE resulted in an R2
value of 0.30.
During the study period, device embolization
occurred in 4 dogs, 1 of which had a type IIA PDA
that subsequently was occluded successfully with an
ACDO 1 size larger than the device that embolized. In
this case, inappropriate device under-sizing could have
played a role in the embolization. In the second and
third dogs (Standard poodle and Chihuahua), appropri-
ate device deployment and seating across the pulmonic
ostium were achieved and conﬁrmed by TEE and back-
and-forth motion of the delivery cable before the device
was released. Subsequently, prominent postdeployment
dilatation of the PDA ampulla was documented by
TEE. Dilatation of the ampulla occurred over a period
of time that resulted in embolization 5–10 minutes after
the device was released in 1 dog and after 28 minutes in
the second dog in which the ampulla diameter 3 mm
above the pulmonary ostium increased by 4.3 mm and
2.0 mm, respectively. The PDA anatomy in both of
these dogs was type IIB. In the fourth dog, another
type IIA PDA, embolization was delayed. Inappropriate
postoperative patient conﬁnement at home was deter-
mined to be the likely cause of embolization rather than
sizing error in this dog.11 Four embolizations after 152
ACDO device deployments represents an embolization
rate of 2.6% over the 8-year study period. Of these,
only 1 dog (the delayed embolization) experienced a
fatal complication during this study period. Although
not considered a true complication, in 1 dog the proxi-
mal disk did not take its normal shape in the ampulla.12
The PDA in this dog was considered to have type I
anatomy with a narrow ampulla and MDD of 1 mm.
An embolization coil was not considered in this dog
because of morphology, and a size 3 ACDO was
deployed. The proximal disk was too large for the
ampulla but was diﬃcult to retract back into the cathe-
ter. Transesophageal echocardiography conﬁrmed the
disk was entirely within the ampulla and had com-
pletely occluded ﬂow through the PDA. Finally, in 1
dog, an ACDO was purposefully deployed entirely
within the ductal ampulla because of improper ACDO
seating across the pulmonary ostium and the decision
that a vascular plug would be insuﬃcient for closure as
assessed by TEE. No residual ﬂow was detected in this
dog during a 24-hour postoperative echocardiogram or
at a subsequent reevaluation echocardiogram 27 months
after ACDO placement.
Discussion
The data presented here support the conclusion that
PDA anatomy varies considerably among individual
dogs, with a large range of possible ACDO device sizes
potentially required for a given body weight. Correla-
tions between body weight and ACDO size, MDD-A,
and MDD-TEE all were relatively poor based on R2
values, indicating that a minimal amount of the vari-
ability in these variables was attributable to changes in
body weight. These ﬁndings support the previous con-
clusion that there is no correlation between body size
and angiographically measured MDD in dogs,7 and
expand this conclusion to include MDD measured with
TEE as well. Current results are also consistent with
data from humans, where no relationships were found
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among diameters, angiographic ductal classiﬁcations,
patient ages, or patient body weights.13
Some degree of correlation between ACDO size and
body weight is intrinsically unavoidable because of limi-
tations in catheter accommodation, and thus ACDO
device size, imposed by the femoral artery diameter in
patients of smaller size. In fact, femoral artery size is
often a rate-limiting variable that dictates that alternate
methods of PDA correction such as surgical ligation be
chosen for the smallest patient population. This limita-
tion is overcome in patients of larger size, because any
ACDO size potentially could be deployed in a larger
patient with an appropriately sized femoral artery. This
diﬀerence can be appreciated when reviewing Table 1,
in which the narrowest ACDO size range is observed in
the smallest weight range (0–5 kg), and substantial
expansion in the ACDO size range is seen in higher
weight brackets. In the 25.1–30 kg range, for example,
ACDO devices at the smallest end of the spectrum were
deployed, as were ACDO devices toward the largest
end of the spectrum. From an inventory perspective,
approximately two-thirds of the study population
(n = 99) weighed ≤15 kg, with deployed ACDO sizes
ranging from 3 up to 12. The most common ACDO
sizes deployed in the dogs that weighed ≤15 kg were
sizes 3 through 6 (n = 75), representing 76% of the
devices deployed in this population, or approximately
57% of the devices deployed in the entire study popula-
tion (n = 86). Thus, it is likely prudent to maintain an
inventory that at minimum encompasses these 4 ACDO
sizes.
Complications related to device sizing in our study
were rare, suggesting that in the majority of cases,
appropriate device sizing was achieved based on MDD-
A, MDD-TEE or, as is often the case at our institution,
a combination of these measurement modalities. In our
experience, 3-dimensional TEE has the potential to fur-
ther improve ability to accurately measure the MDD in
multiple dimensions and thus could lead to even fewer
sizing complications in the future. We did not study this
modality nor was any comparison made between MDD
measured by TTE and MDD measured by angiography
or TEE. Although not previously a reported cause of
device embolization, dilatation of the PDA ampulla
after ductal occlusion with an ACDO is reported in
dogs, with signiﬁcant increases in the length and width
of the ampulla compared to pre-occlusion dimensions.5
In the 2 cases of embolization in our study in which
ampulla dilatation occurred, prominent dilatation of the
ampulla after occlusion was documented by TEE and
Table 1. ACDO device sizes deployed across various body weight ranges. ACDO, Amplatz Canine Duct Occluder.
Weight
range
(kg)
Number
of dogs
(n = 152)
ACDO
size
range
ACDO 3
(n = 22)
ACDO 4
(n = 20)
ACDO 5
(n = 22)
ACDO 6
(n = 22)
ACDO 7
(n = 12)
ACDO 8
(n = 16)
ACDO 9
(n = 14)
ACDO 10
(n = 11)
ACDO 12
(n = 7)
ACDO 14
(n = 6)
0–5 42 3–7 14 11 10 5 2 0 0 0 0 0
5.1–10 37 3–12 6 5 8 7 3 3 3 1 1 0
10.1–15 20 3–10 1 2 2 4 3 4 2 2 0 0
15.1–20 15 4–14 0 1 0 2 2 1 3 4 0 2
20.1–25 19 5–14 0 0 2 2 1 5 2 3 2 2
25.1–30 9 3–12 1 1 0 0 0 2 1 1 3 0
30.1–35 3 7–12 0 0 0 0 1 0 1 0 1 0
35.1–40 7 6–14 0 0 0 2 0 1 2 0 0 2
Fig 1. Scatterplot data with regression line depicting ACDO device size deployed versus body weight (kg) in 152 dogs. ACDO, Amplatz
Canine Duct Occluder.
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would not have been recognized as a contributing factor
without on going TEE monitoring postdeployment.
Whether type IIB ductal anatomy played a role in pos-
tocclusion dilatation is diﬃcult to determine with such
a small number of cases. Type IIB PDAs previously
have been theorized to provide less device stability than
type IIA PDAs, with a possible need for slightly larger
device sizing proposed with this anatomical variant.14
Our study provides useful information for interven-
tional cardiologists performing minimally invasive PDA
occlusion with ACDO devices by oﬀering insight into
the range of device sizes that may be required for dogs
of diﬀerent body weights as well as the most commonly
used device sizes in a large population for purposes of
inventory planning. Additionally, it reinforces the
notion that PDA anatomy varies on an individual basis,
making weight-based assumptions about expected
ACDO device size for any given patient unwise.
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